AstraZeneca Unveils Latest Research Across Key Respiratory and Immune-Mediated Diseases at ATS 2024 Showcasing Strength of Its Broad Pipeline and Portfolio
May 02, 2024
May 02, 2024
WILMINGTON, Delaware, May 2 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on May 1, 2024:
* * *
New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca's innovation and commitment to transform care in COPD
* * *
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Con . . .
* * *
New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca's innovation and commitment to transform care in COPD
* * *
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Con . . .